AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02592629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: used with Kenalog in shoulder injection and as topical anesthetic as subcutaneous injection
Study NCT02592629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ethyl chloride
Description: topical spray
Study NCT02592629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kenalog
Description: used with lidocaine in shoulder injection
Study NCT02076256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The helping relationships intervention program
Study NCT00256048 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasojejunal feeding
Study NCT00066625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT00066625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT00066625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00066625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00171340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole tablets 2.5 mg/day taken orally for 5 years.
Study NCT03570281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: Edoxaban, per oral, 60mg qd (may consider reduced dose to 30mg qd in patients with proper clinical reason by attending physician, estimated creatinine clearance of 30 to 50 ml per minute, a body weight of 60 kg or less, or the concomitant use of verapamil or quinidine), for 90 days.
Study NCT03570281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin, subcutaneous injection, 1mg/kg BID (may consider reduced dose to 1mg/kg qd in patients with proper clinical reason by attending physician, Creatinine clearance \<30 mL/min), for 90 days.
Study NCT02668107 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hammock positioning
Description: Babies in the intervention group (IG), will be positioned supine in a hammock(hammock positioning) in the incubator, with the appropriate postural adjustments.
Study NCT01597128 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flex HD
Description: Flex HD mesh for hernia repair
Study NCT02771041 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: medical consultation 8 days before surgery
Description: This consultation would serve to explain to the patient the early course of care, give advice and help to anticipate acts for its release post-operative as, for example, contact a physical therapist and a nurse or check to their community pharmacy if their heparin stock is enough and to answer any questions.
Study NCT03172052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: streptokinase
Description: • Chemical adhesiolysis by instillation of streptokinase at a dose of 250,000 I.U dissolved in 40 ml of normal saline will be instil in the pleural cavity through the chest tube. we planning to continue the daily instillation as long as the drained fluid volume is >100 cc with a maximum of 14 doses and to stop further instillation if severe complication occurred.
Study NCT01597128 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Strattice
Description: Strattice mesh for hernia repair
Study NCT00667745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: Lithium was started at 300 mg and then increased to 600 mg after 3 days. Lithium doses were maintained at 600 mg per day for 8 weeks, but may have been adjusted after that time as needed up to a serum level of 1.2 mEq/L.
Study NCT00667745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized Treatment (OPT)
Description: The foundation of OPT was to maintain treatment that will typically include at least one FDA-approved mood stabilizer other than lithium (e.g., divalproex, carbamazepine, risperidone, quetiapine, olanzapine, aripiprazole, ziprasidone) and to follow the recommendations summarized in the evidence-based stages of the Texas Implementation of Medication Algorithm (TIMA) revised guidelines.
Study NCT00667745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimized Treatment (OPT)
Description: The foundation of OPT was to maintain treatment that will typically include at least one FDA-approved mood stabilizer other than lithium (e.g., divalproex, carbamazepine, risperidone, quetiapine, olanzapine, aripiprazole, ziprasidone) and to follow the recommendations summarized in the evidence-based stages of the Texas Implementation of Medication Algorithm (TIMA) revised guidelines.
Study NCT05161507 — intervention group
Intervention type: PROCEDURE
Intervention: Magseed
Description: Patients with the non-palpable histologically confirmed breast cancer lesion - the tumor lesion will be labeled with Magseed and patient will undergo breast-conserving surgery and sentinel lymph node detection with Tc99.
Study NCT05161507 — intervention group
Intervention type: PROCEDURE
Intervention: Magtrace
Description: Patients with the palpable histologically confirmed breast cancer lesion - The Magtrace will be injected preoperatively into the tumor and detected by Sentimag. Patient will undergo sentinel lymph node detection with Tc99 and Sentimag localization system with breast surgery.
Study NCT05161507 — intervention group
Intervention type: PROCEDURE
Intervention: Axillary lymph node metastasis - needle biopsy
Description: Patients with the histologically confirmed breast cancer lesion with Axillary lymph node metastasis with pathologic confirmation by needle biopsy - the positive axillary lymph node lesion will be labeled with Magseed before the neoadjuvant systemic therapy, and later during target axillary dissection will be performed the biopsy of labeled lymph node during breast surgery.
Study NCT04872829 — intervention group
Intervention type: DEVICE
Intervention: cataract surgery
Description: All patients underwent cataract surgery under 1 year of age (mean age 8 months, range 6-12) performed with the same surgical technique: two 1.2 mm clear corneal incision, continuous curvilinear capsulorhexis with a diameter of approximately 6.0 mm and intraocular lens implantation, posterior capsulotomy and anterior vitrectomy.~IOL power was calculated using Sanders-Retzlaff-Kraff (SRK)/II formula. Multifocal IOL implantated was Alcon AcrySof ReSTOR SN60D3, while the monofocal one was Alcon AcrySof SN60AT.~According to the Infant Aphakia treatment Study, the IOL power was calculated as a function of the child age17, with an undercorrection ranging from 4 to 6 D.
Study NCT03140735 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Study the relationship between the arterial rigidity of large vessels and the presence and severity of degenerative aortic constriction
Description: Study the relationship between the arterial rigidity of large vessels and the presence and severity of degenerative aortic constriction
Study NCT03514134 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Services as Usual
Description: Study participants will be receiving their community-based or school-based services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
Study NCT03514134 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Services as Usual
Description: Study participants will be receiving their community-based or school-based services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
Study NCT03140735 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group without heart disease
Description: Control group without heart disease
Study NCT03172052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MESNA (2-mercaptoethane sulfonate Na)
Description: • Chemical adhesiolysis by instillation of MESNA at a dose of 1800 mg of MESNA i.e. 3 ampoules ( each ampoule contains 3ml and each ml contains 200 mg of MESNA) will be diluted with 20ml of Normal Saline and will be injected into the pleural cavity through the chest tube for three consecutive days.
Study NCT02686554 — intervention group
Intervention type: OTHER
Intervention: Neuropsychological assessment
Description: The patients perform tests to assess their cognitive abilities
Study NCT01123083 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Otelixizumab
Description: infusion
Study NCT01123083 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infusion
Study NCT04297982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mandala Activity
Description: Mandala is a method of expressing one's feelings and thoughts. The person draws and paints the paper in a round shape.
Study NCT03730519 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Baroreflex Activation Therapy with Barostim Neo
Description: Baroreflex activation therapy (BAT) delivers electrical field stimulation at the carotid sinus to lower BP.
Study NCT04297982 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Routine nursing care
Description: Interventions routinely implemented by nurses in the clinic
Study NCT04297982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine nursing care
Description: Interventions routinely implemented by nurses in the clinic
Study NCT04169763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT04169763 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT
Study NCT04169763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Description: Given PO
Study NCT00913822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desipramine Hydrochloride 100 mg Tablets (Cord Laboratories)
Study NCT00913822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norpramin 100 mg Tablets (Merrell Dow Pharmaceuticals, Inc.)
Study NCT03733548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RELAX
Description: Regulating Emotions Like An eXpert (RELAX) consists of 8 weekly, 90-minute sessions delivered (60 minutes of parents and adolescents meeting separately, 30 minutes of a combined meeting) in a group format. RELAX equips adolescents with emotion regulation and conflict management skills. This program includes a parent involvement component designed to help parents support adolescents' use of these skills. Each week skills will be discussed and practiced in group, and a skills rehearsal homework activity will be assigned. Following the program, an 8-week follow-up review session will be offered. Additionally, a single 60 minute focus group will be held following the review session to solicit parent and adolescent feedback on the intervention.
Study NCT00861887 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard Vancomycin
Description: Vancomycin treatment 125 mg po every 6 hours x 2 weeks
Study NCT04178941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit and Feedback
Description: The audit and feedback intervention includes providing each hospital's own continuous pulse oximetry use data back to them on a weekly basis for review and action.
Study NCT04178941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational outreach
Description: Educational outreach includes staff-targeted educational materials and outreach sessions summarizing the current evidence and guideline recommendations for continuous pulse oximetry use in bronchiolitis.
Study NCT02310295 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: focal macular laser therapy
Study NCT03172052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical thoracoscopy
Description: Medical thoracoscopy procedure will be carried at endoscopy unit at chest department via, semi rigid thoracoscope (LTF; Olympus; Tokyo, Japan).
Study NCT00861887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Vancomycin
Description: Vancomycin treatment 125 mg po every 6 hours x 2 weeks
Study NCT00861887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended Vancomycin
Description: Vancomycin 125 mg every 6 hours x 2 weeks
Study NCT03172052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video assisted thoracoscopy (VATS)
Description: Video assisted thoracoscopy (VATS) at cardiothoracic surgery department.
Study NCT02310295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Intravitreal injection of Bevacizumab
Study NCT02105311 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty
Description: Selective laser trabeculoplasty platform The Lumenis Selecta® Duet™ (Lumenis Ltd., Yokneam, Israel)
Study NCT02105311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost
Description: Travoprost benzalkonium-free ophthalmic solution (40 microgram/ml) (Alcon Laboratories, Inc., Fort Worth, TX, USA)
Study NCT02498535 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitric Oxide 160 ppm
Description: Nitric Oxide 160 ppm
Study NCT02498535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide 160 ppm
Description: Nitric Oxide 160 ppm
Study NCT03052972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18
Description: 370 megabecquerel (MBq)(10 millicurie \[mCi\]) single dose
Study NCT03052972 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain PET scan
Description: positron emission tomography (PET) scan of the brain
Study NCT00655278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T2000
Description: T2000 at previous most effective, well-tolerated dose (600-1000mg daily)
Study NCT02288208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiviral Therapy (tenofovir or entecavir)
Study NCT02288208 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antiviral Therapy (tenofovir or entecavir)
Study NCT02288208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birinapant
Study NCT02288208 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for birinapant)
Study NCT03829007 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PD-L1 imaging
Description: 89Zr-durvalumab injection followed by a PET/CT scan 5 days after injection
Study NCT03829007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab treatment is initiated after the PET/CT scan in a fixed dose of 1500 mg iv q4w
Study NCT03288402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ongoing fasted state, intake of caffeine containing beverages or 5-item English breakfast
Description: effects of ongoing fasted state; or intake caffeine containing beverages; or 5-item English breakfast on plasma CgA measurements, in series blood tests every 30 min over 180 min
Study NCT02948725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cross-education + standard rehabilitation
Study NCT02978352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: learning
Study NCT02310295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: Intravitreal injection of Triamcinolone Acetonide
Study NCT01138215 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VZV vaccination
Description: Dose : 0.5 ml Route : subcutaneous injection (SC)
Study NCT00755118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin (I.V) 85mg/m2 on week 1 and week 3 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
Study NCT00755118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-Fluorouracil (I.V) 1750mg/m2 on week 1,2,3 and 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
Study NCT03262961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil 20 MG
Study NCT03262961 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Study NCT05967754 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: polysomnography
Description: polysomnography and serum uric acid measurement
Study NCT03369158 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: patient specific pedicle screw positioning guide
Study NCT03369158 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free hand technique pedicle screw positioning
Study NCT03369158 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MUST pedicle screw
Study NCT03369158 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MUST pedicle screw
Study NCT00980044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: Oral Medication
Study NCT00980044 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Medication
Study NCT01296308 — intervention group
Intervention type: OTHER
Intervention: inpatient integrative treatment
Description: two weeks inpatient integrative therapy: conventional medicine, traditional European and Chinese medicine (TCM), mind-body medicine, physical therapy, lifestyle modification program: nutrition advices, stress management, exercise training
Study NCT03502681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Days 1, 15~Eribulin mesylate:~Dose level -1: 0.7mg/m\^2;~Dose level 0: 1.1 mg/m\^2;~Dose level +1: 1.4 mg/m\^2
Study NCT03502681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Days 1, 15 Avelumab (10mg/kg)
Study NCT01871649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: golimumab
Description: golimumab 50mg subcutaneous injections (in combination with methotrexate), once a month, for a period of 22 weeks
Study NCT01871649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: Methotrexate will be started at a dosage of 15 mg/week orally and, if well tolerated, increased to 20mg/week at week 4 and 25mg/week at week 8 of the trial. If well tolerated, the maximum dose of 25 mg/week will be sustained until end of study (week 50). Folic acid 5 mg/week will be administered orally one day after the MTX intake.
Study NCT00755118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin (I.V) 500mg/m2 on week 1,2,3 and 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
Study NCT00755118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (I.V) 10mg/Kg on week 1 and week 3 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
Study NCT00755118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan (I.V) 110mg/m2 on week 2 and week 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
Study NCT00755118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab (I.V) 500mg/m2 on week 2 and week 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
Study NCT04090190 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxybutynin, Solifenacin, Tolterodine, Trospium, or Fesoterodine
Description: Study participants will be evaluated for urgency urinary incontinence and will be offered treatment with a standard of care anticholinergic medication for 6 weeks. All study participants will fill out the UDI-6 and two day bladder diary at baseline before starting anticholinergic medication treatment. Participants will then provide a urine sample and blood draw to be assessed for urinary microbiome and inflammation. Anticholinergic medication will be taken daily for 6 weeks and the same procedures (UDI-6 questionnaire, bladder diary, urine sample except the blood draw for assessment) will be performed at the 6-week time period.
Study NCT02614118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac tromethamine
Description: 10 mg oral Ketorolac tromethamine 45 minutes before root canal treatment
Study NCT02614118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1000 mg oral Acetaminophen along with10 mg oral Ketorolac tromethamine 45 minutes before root canal treatment.
Study NCT02614118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 45 minutes before root canal treatment
Study NCT00457691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 fluorouracil
Description: 400mg/m2 bolus injection day 1 followed by 2400mg/m2 continuous infusion for 46 hours every 14 days
Study NCT00457691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: 180mg/m2 iv day 1 every 14 days
Study NCT00457691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levo- leucovorin
Description: 200mg/m2 iv; day 1 every 14 days
Study NCT00457691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: 37.5mg of blinded therapy every day for 28 days followed by 14 days of blinded therapy free period
Study NCT00457691 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5 fluorouracil
Description: 400mg/m2 bolus injection day 1 followed by 2400mg/m2 continuous infusion for 46 hours every 14 days